The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | CD20/CD3 bispecific antibodies in R/R DLBCL: glofitamab and epcoritamab
Chris Fox, MBChB(Hons), MRCP, FRCPath, University of Nottingham, Nottingham, UK, discusses the role of CD20/CD3 bispecific antibodies in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab are currently utilized in third-line therapy for patients who have relapsed post-CAR-T or are ineligible, achieving complete response (CR) rates of up to 40%. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy/advisory boards: AbbVie, AstraZeneca, Atarabio, BMS, GenMab, Gilead/Kite, Incyte, Janssen, Lilly, Morphosys, Ono, Roche, SERB, SOBI, Takeda; Educational activities: AbbVie, Kite/Gilead, Incyte, Janssen, Roche, Takeda, SERB; Travel: Roche, Kite/Gilead; Research funding: BeiGene, AbbVie/GenMab.
